Connect with us
[the_ad id="89560"]

Health

UK pediatrician who led review of child ‘transitions’ says US medical groups ‘misleading the public’

Published

6 minute read

Dr. Hilary Cass, author of the Cass Review

From LifeSiteNews

By Calvin Freiburger

The typically left-wing New York Times published an interview on Monday with consultant pediatrician Dr. Hilary Cass on her comprehensive review of so-called “gender medicine” in the United Kingdom, indicating that awareness of the damage due to surgical and chemical “transitioning” continues to spread despite the best efforts of LGBT activists.

Released in April, 366-page Cass Review was commissioned by National Health Service (NHS) England following ongoing scandals about the practices of British “gender clinics” such as the Gender Identity Development Service (GIDS), operated by the Tavistock and Portman NHS Foundation Trust. The four-year project consisted of comprehensive reviews of current research and international standards, as well as extensive interviews with gender-confused children and adults, family members, detransitioners, doctors, and activists.

It found that “gender medicine” is “built on shaky foundations” and that while such interventions require a great deal of caution, “quite the reverse happened in the field of [so-called] gender care for children,” and that “[w]hile a considerable amount of research has been published in this field, systematic evidence reviews demonstrated the poor quality of the published studies, meaning there is not a reliable evidence base upon which to make clinical decisions, or for children and their families to make informed choices.” Her findings led NHS to stop prescribing puberty blockers to children with gender confusion earlier this year.

Speaking to the Times, Cass explained that she was planning her retirement when she was first asked to tackle the project and was initially apprehensive about wading into the controversy.

“The most important concern for me is just how poor the evidence base is in this area,” she said. “Some people have questioned, ‘Did we set a higher bar for this group of young people?’ We absolutely didn’t. The real problem is that the evidence is very weak compared to many other areas of pediatric practice.”

The Times acknowledged that her “findings are in line with several European countries that have limited the treatments [sic] after scientific reviews. But in America, where nearly two dozen states have banned the care outright, medical groups have endorsed the treatments as evidence-based and necessary,” including groups the paper contacted for its latest story. Cass described American medical consensus as “out of date” on the issue.

“When I was president of the Royal College of Pediatrics and Child Health, we did some great work with the A.A.P. [American Academy of Pediatrics],” she elaborated. “They are an organization that I have enormous respect for. But I respectfully disagree with them on holding on to a position that is now demonstrated to be out of date by multiple systematic reviews.”

“It wouldn’t be too much of a problem if people were saying ‘This is clinical consensus and we’re not sure,” she added. “But what some organizations are doing is doubling down on saying the evidence is good. And I think that’s where you’re misleading the public. You need to be honest about the strength of the evidence and say what you’re going to do to improve it.”

significant body of evidence shows that “affirming” gender confusion carries serious harms, especially when done with impressionable children who lack the mental development, emotional maturity, and life experience to consider the long-term ramifications of the decisions being pushed on them.

Yet while mounting evidence against youth “gender transitions” is prompting European nations such as the United Kingdom and France, which are normally to the left of America, to move away from the practice, in America, the medical establishment and the Biden administration continues to dig in their heels, despite Biden’s own Substance Abuse & Mental Health Services Administration (SAMHSA) releasing a since-deleted report last year acknowledging that “lesbian, gay, and bisexual adults are more likely than straight adults to use substances, experience mental health conditions including major depressive episodes, and experience serious thoughts of suicide.”

The White House’s comprehensive pursuit of the transgender agenda has included reopening the military to recruits afflicted with gender dysphoria, promoting gender ideology within the military (including “diversity” and drag events on military bases), holding White House events to “affirm transgender kids,” condemning state laws against underage “transitions” as “close to sinful,” promoting underage “transitions” (potentially at taxpayer expense) as a “best practice,” and trying to force federally funded schools to let males into female athletic competitions and restrooms.

Business

Trump signs order reclassifying marijuana as Schedule III drug

Published on

From The Center Square

By

President Donald Trump signed an executive order moving marijuana from a Schedule I to a Schedule III controlled substance, despite many Republican lawmakers urging him not to.

“I want to emphasize that the order I am about to sign is not the legalization [of] marijuana in any way, shape, or form – and in no way sanctions its use as a recreational drug,” Trump said. “It’s never safe to use powerful controlled substances in recreational manners, especially in this case.”

“Young Americans are especially at risk, so unless a drug is recommended by a doctor for medical reasons, just don’t do it,” he added. “At the same time, the facts compel the federal government to recognize that marijuana can be legitimate in terms of medical applications when carefully administered.”

Under the Controlled Substances Act, Schedule I drugs are defined as having a high potential for abuse and no accepted medical use. Schedule III drugs – such as anabolic steroids, ketamine, and testosterone – are defined as having a moderate potential for abuse and accepted medical uses.

Although marijuana is still illegal at the federal level, 24 states and the District of Columbia have fully legalized marijuana within their borders, while 13 other states allow for medical marijuana.

Advocates for easing marijuana restrictions argue it will accelerate scientific research on the drug and allow the commercial marijuana industry to boom. Now that marijuana is no longer a Schedule I drug, businesses will claim an estimated $2.3 billion in tax breaks.

Chair of The Marijuana Policy Project Betty Aldworth said the reclassification “marks a symbolic victory and a recalibration of decades of federal misclassification.”

“Cannabis regulation is not a fringe experiment – it is a $38 billion economic engine operating under state-legal frameworks in nearly half of the country that has delivered overall positive social, educational, medical, and economic benefits, including correlation with reductions in youth use in states where it’s legal,” Aldworth said.

Opponents of the reclassification, including 22 Republican senators who sent Trump a warning letter Wednesday, point out the negative health impact of marijuana use and its effects on occupational and road safety.

“The only winners from rescheduling will be bad actors such as Communist China, while Americans will be left paying the bill. Marijuana continues to fit the definition of a Schedule I drug due to its high potential for abuse and its lack of an FDA-approved use,” the lawmakers wrote. “We cannot reindustrialize America if we encourage marijuana use.”

Marijuana usage is linked to mental disorders like depression, suicidal ideation, and psychotic episodes; impairs driving and athletic performance; and can cause permanent IQ loss when used at a young age, according to the Substance Abuse and Mental Health Administration.

Additionally, research shows that “people who use marijuana are more likely to have relationship problems, worse educational outcomes, lower career achievement, and reduced life satisfaction,” SAMHA says.

Continue Reading

Health

Saskatchewan woman approved for euthanasia urged to seek medical help in Canada rather than US

Published on

From LifeSiteNews

By Anthony Murdoch

Saskatchewan Premier Scott Moe encouraged Jolene Van Alstine, who has a rare disease, to work with his government on a solution.

Saskatchewan Premier Scott Moe is urging a woman with a rare disease, who has been approved to die by euthanasia because she can’t get proper care, to instead work with his government on a solution.

As reported by LifeSiteNews last week, Saskatchewan resident Jolene Van Alstine was approved to die by state-sanctioned euthanasia because she has had to endure long wait times for what she considers to be proper care for a rare parathyroid disease.

Van Alstine’s condition, normocalcemic primary hyperparathyroidism (nPHPT), causes her to experience vomiting, nausea, and bone pain.

As a result of Van Alstine’s frustrations with the healthcare system, she applied for Canada’s Medical Assistance in Dying (MAiD) and was approved for a January 7, 2026, death date.

Her case drew the attention of American media personality Glenn Beck, who has been in contact with Van Alstine to determine whether she can get the surgery done in the United States. Even the administration of U.S. President Donald Trump has been briefed on the matter.

According to Moe, Van Alstine has taken her case to Saskatchewan Health Minister Jeremy Cockrill, asking for help.

“There has been an opportunity to see specialists in Saskatchewan and outside of Saskatchewan, and those conversations about maybe potentially seeing additional specialists continue with the minister’s office and the Ministry of Health,” Moe said yesterday at a press conference.

“I would hope that she’d continue to work with the Ministry of Health, because I think there’s work going on to see even additional specialists at this point,”

A recent Euthanasia Prevention Coalition report revealed that Canada has euthanized 90,000 people since 2016, the year it was legalized.

As reported by LifeSiteNews, over 23,000 Canadians have died while on wait lists for medical care as Prime Minister Mark Carney’s Liberal government focuses on euthanasia expansions.

Continue Reading

Trending

X